Compare Dollar General Corp. (DG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Mesoblast Limited — how do they compare? Dollar General Corp. trades at $120.07 (market cap $27.00B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Dollar General Corp. is far larger — about 12.5× Mesoblast Limited's market cap, and Dollar General Corp. pays a 1.93% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DG | MESO | |
|---|---|---|
Market Cap | $27.00B | $2.16B |
Sector | Consumer Staples | Technology |
52-Week High | $156.26 | $20.96 |
52-Week Low | $95.94 | $12.88 |
Enterprise Value | $41.45B | $2.17B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $126.59, down 0.69% on the day, with strong technical momentum indicated by bullish moving averages and oversold RSI conditions. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.00 exceeding expectations of $1.89, while maintaining solid profitability metrics including 18.91% ROE. Recent cash flow trends show improvement with 2025 net cash flow of $395 million, and the balance sheet reflects declining debt-to-asset ratios from 22.73% to 20.03% year-over-year.
The outlook remains positive with analyst consensus favoring Buy ratings (52%) and a $128.45 price target offering modest upside. Key opportunities include consumer trade-down benefits and margin improvement, while risks involve competition from Walmart and Amazon, market saturation concerns, and ongoing cost pressures. The stock presents a value proposition with attractive P/S (0.65) and P/E (17.91) multiples relative to historical norms.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
